MA45811A - Méthodes et compositions de traitement de maladie. - Google Patents

Méthodes et compositions de traitement de maladie.

Info

Publication number
MA45811A
MA45811A MA045811A MA45811A MA45811A MA 45811 A MA45811 A MA 45811A MA 045811 A MA045811 A MA 045811A MA 45811 A MA45811 A MA 45811A MA 45811 A MA45811 A MA 45811A
Authority
MA
Morocco
Prior art keywords
treatment
methods
disease
compositions
myelofibrosis
Prior art date
Application number
MA045811A
Other languages
English (en)
Inventor
Ravindra Kumar
Sai Rajasekhar Suragani Naga Venkata
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MA45811A publication Critical patent/MA45811A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

La présente invention concerne, en partie, des méthodes de traitement, de prévention ou de réduction du taux de progression et / ou de la gravité de la myélofibrose ou d’une ou plusieurs complications de la myélofibrose (hématopoïèse extramédullaire, splénomégalie, anémie et fibrose). Selon certains aspects, la présente invention concerne des antagonistes actriib destinés à être utilisés dans le traitement, la prévention ou la réduction du taux de progression et / ou de la gravité d'une ou plusieurs complications associées au traitement par un inhibiteur de janus kinase chez un patient (par exemple l'anémie).
MA045811A 2016-07-27 2017-07-26 Méthodes et compositions de traitement de maladie. MA45811A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662367289P 2016-07-27 2016-07-27

Publications (1)

Publication Number Publication Date
MA45811A true MA45811A (fr) 2019-06-05

Family

ID=61017458

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045811A MA45811A (fr) 2016-07-27 2017-07-26 Méthodes et compositions de traitement de maladie.

Country Status (12)

Country Link
US (2) US20180050085A1 (fr)
EP (1) EP3490582A4 (fr)
JP (2) JP7264580B2 (fr)
KR (1) KR20190040972A (fr)
CN (1) CN109789184A (fr)
AU (1) AU2017302282A1 (fr)
BR (1) BR112019001615A2 (fr)
CA (1) CA3031909A1 (fr)
EA (1) EA201990226A1 (fr)
MA (1) MA45811A (fr)
MX (1) MX2019001043A (fr)
WO (1) WO2018022762A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2890217C (fr) 2012-11-02 2021-07-20 Yifu FANG Antagonistes d'activine-actrii et utilisations pour le traitement de troubles osseux et autres
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
WO2016187378A1 (fr) 2015-05-20 2016-11-24 Celgene Corporation Procédés de culture de cellules in vitro pour la bêta-thalassémie à l'aide de pièges à ligands du récepteur de l'activine de type ii
AU2016359695A1 (en) 2015-11-23 2018-06-14 Acceleron Pharma Inc. Methods for treating eye disorders
WO2018089715A1 (fr) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Variants de type iia du récepteur de l'activine et leurs méthodes d'utilisation
EP3638243A4 (fr) * 2017-06-14 2021-03-17 Celgene Corporation Méthodes de traitement de la myélofibrose associée à un néoplasme myéloprolifératif et de l'anémie
EP3706777A4 (fr) 2017-11-09 2021-06-23 Keros Therapeutics, Inc. Variants de type iia du récepteur de l'activine et leurs méthodes d'utilisation
EP3737406A4 (fr) 2018-01-12 2021-11-03 Keros Therapeutics, Inc. Variants de type iib du récepteur de l'activine et leurs méthodes d'utilisation
JP7405772B2 (ja) * 2018-05-09 2023-12-26 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物
AU2020356575A1 (en) * 2019-09-27 2022-04-14 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
US20220372136A1 (en) * 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating anemia of chronic disease
MX2022012610A (es) * 2020-04-13 2022-11-07 Celgene Corp Metodos para tratar anemia usando una trampa de ligando de receptor de activina de tipo iib (actriib) y fedratinib.
US20230210827A1 (en) * 2020-05-15 2023-07-06 Celgene Corporation Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors
WO2023023345A2 (fr) * 2021-08-19 2023-02-23 Keros Therapeutics, Inc. Procédés d'utilisation d'inhibiteurs de la signalisation du type ii du récepteur de l'activine
WO2023108137A1 (fr) * 2021-12-10 2023-06-15 Biogen Ma Inc. Protéines actriib modifiées et leurs procédés d'utilisation

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0786469T3 (da) 1990-06-11 2006-07-10 Gilead Sciences Inc Nukleinsyreligander
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
EP1997894B1 (fr) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Protéine de liaison biosynthétique pour un marqueur du cancer
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2217545A1 (fr) 1995-04-11 1996-10-17 Marc Vidal Systemes d'hybrides doubles inverses
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6423501B2 (en) 1996-12-13 2002-07-23 Beth Israel Deaconess Medical Center Calcium-independent negative regulation by CD81 of receptor signaling
US6011577A (en) 1997-06-30 2000-01-04 Polaroid Corporation Modular optical print head assembly
WO1999010364A1 (fr) 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatine-3
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
CA2355215A1 (fr) 1998-12-28 2000-07-06 Jim Wells Identification de ligands de type petites molecules organiques, destines a former des liaisons
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2003517580A (ja) 1999-01-21 2003-05-27 メタモーフイクス・インコーポレーテツド 増殖分化因子インヒビター及びそれらの用途
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
ATE428719T1 (de) 1999-07-29 2009-05-15 Gilead Sciences Inc Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
WO2001044463A1 (fr) 1999-12-15 2001-06-21 Genentech, Inc. Balayage aveugle, procede combinatoire permettant la representation d'epitopes de proteines fonctionnelles
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101940189A (zh) 2000-11-30 2011-01-12 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
AU2003239966B9 (en) 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
EP1585767A2 (fr) 2003-01-16 2005-10-19 Genentech, Inc. Banques de phages anticorps synthetiques
US20070135336A1 (en) 2003-09-15 2007-06-14 De Kretser David Follistatin isoforms and uses thereof
JP5128935B2 (ja) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド ヒト化抗ＴＧＦ−β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP2360186B1 (fr) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anticorps dirigés contre la sélectine P
CA2891010C (fr) 2004-07-23 2022-09-20 Acceleron Pharma Inc. Polypeptides du recepteur actrii, procedes et compositions correspondants
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
EP1957531B1 (fr) 2005-11-07 2016-04-13 Genentech, Inc. Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
JP5261187B2 (ja) 2005-11-23 2013-08-14 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａアンタゴニストおよび骨成長を促進するための使用
EP1973951A2 (fr) 2005-12-02 2008-10-01 Genentech, Inc. Polypeptides de liaison avec des sequences de diversite limitees
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
WO2008030367A2 (fr) 2006-09-01 2008-03-13 The General Hospital Corporation Inhibiteurs sélectifs de la myostatine
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
HUE051137T2 (hu) * 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
RU2642302C1 (ru) * 2009-08-13 2018-01-24 Акселерон Фарма Инк. Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов
WO2012027065A2 (fr) * 2010-08-27 2012-03-01 Celgene Corporation Polythérapie pour traiter des maladies
AU2014354769A1 (en) * 2013-11-26 2016-05-26 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
WO2015143403A1 (fr) * 2014-03-21 2015-09-24 Acceleron Pharma, Inc. Méthodes pour augmenter les taux d'érythrocytes et traiter l'érythropoïèse inefficace par inhibition de l'activine b et/ou de gdf11
EP3154566B1 (fr) * 2014-06-13 2022-08-03 Acceleron Pharma Inc. Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
WO2017079591A2 (fr) * 2015-11-04 2017-05-11 Acceleron Pharma Inc. Méthodes pour augmenter les taux d'érythrocytes et traiter l'érythropoïèse inefficace
EP3638243A4 (fr) * 2017-06-14 2021-03-17 Celgene Corporation Méthodes de traitement de la myélofibrose associée à un néoplasme myéloprolifératif et de l'anémie

Also Published As

Publication number Publication date
CN109789184A (zh) 2019-05-21
AU2017302282A1 (en) 2019-02-07
JP2019522022A (ja) 2019-08-08
JP7264580B2 (ja) 2023-04-25
EP3490582A4 (fr) 2020-04-01
EA201990226A1 (ru) 2019-08-30
BR112019001615A2 (pt) 2019-04-30
KR20190040972A (ko) 2019-04-19
US20210322514A1 (en) 2021-10-21
WO2018022762A1 (fr) 2018-02-01
MX2019001043A (es) 2019-09-26
CA3031909A1 (fr) 2018-02-01
EP3490582A1 (fr) 2019-06-05
JP2023014373A (ja) 2023-01-26
US20180050085A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
MA45811A (fr) Méthodes et compositions de traitement de maladie.
MX2021004431A (es) Procesos novedosos.
PH12017500725B1 (en) Indole carboxamide compounds useful as kinase inhibitors
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
DE602004013563D1 (de) Rantagonisten
PH12017500829A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
EA202190377A1 (ru) Композиции ингибиторов cxcr4 и способы получения и применения
MA42811A (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
ATE556060T1 (de) Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
MX2007012374A (es) Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
EA201590353A1 (ru) Способы лечения болезни альцгеймера и фармацевтические композиции
EA202090871A1 (ru) Ингибирование убиквитин-специфической пептидазы 30
ATE535514T1 (de) Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten
MA40769A (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA54386B1 (fr) Modulateurs de trex1
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201991650A1 (ru) Способы лечения неврологических расстройств
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
EA202092225A1 (ru) Соединения и их применение
MX2022007176A (es) 4-((2-oxopyri din-1 (2h)-yl)metil)benzamidas para el tratamiento de la deficiencia de alfa1-antitripsina.
MA39228A1 (fr) Compositions à utiliser pour le traitement d'états allergiques
FR3070263B1 (fr) Composition pour son utilisation dans le traitement et/ou la prevention de l’infertilite
EA201890769A1 (ru) Производные 2,3,4,5-тетрагидропиридин-6-амина